Artiva Biotherapeutics, Inc. (ARTV)Healthcare | Biotechnology | San Diego, United States | NasdaqGM
12.55 USD
+0.44
(3.633%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 12.54 -0.01 (-0.006%) ⇩ (April 17, 2026, 7:50 p.m. EDT) Short-term: ★★★★★ | Long-term: ★★★★☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 6:38 p.m. EDT
Short-term catlike rally driven by FDA Fast-Track designation for AlloNK in Rheumatoid Arthritis; long-term catalyst warranted by strong balance sheet and analyst upgrades despite current earnings burn |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.220718 |
| AutoETS | 0.225085 |
| AutoARIMA | 0.225384 |
| AutoTheta | 0.277409 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 47% |
| H-stat | 4.71 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.135 |
| Excess Kurtosis | 0.82 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 9.95 |
| Market Cap | 310,194,240 |
| Forward P/E | -5.07 |
| Website | https://www.artivabio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 4.2291665 |
| Address1 | 5,505 Morehouse Drive |
| Address2 | Suite 100 |
| All Time High | 17.31 |
| All Time Low | 1.47 |
| Ask | 12.64 |
| Ask Size | 1 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 430,750 |
| Average Daily Volume3 Month | 214,654 |
| Average Volume | 214,654 |
| Average Volume10Days | 430,750 |
| Bid | 12.32 |
| Bid Size | 1 |
| Book Value | 4.527 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 12.55 |
| Current Ratio | 8.609 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 13.2 |
| Day Low | 11.11 |
| Debt To Equity | 9.95 |
| Display Name | Artiva Biotherapeutics |
| Earnings Timestamp End | 1,754,569,800 |
| Earnings Timestamp Start | 1,754,569,800 |
| Ebitda | -87,213,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.444 |
| Enterprise Value | 213,128,240 |
| Eps Current Year | -3.32 |
| Eps Forward | -2.47667 |
| Eps Trailing Twelve Months | -3.43 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.8786 |
| Fifty Day Average Change | 6.6714 |
| Fifty Day Average Change Percent | 1.1348621 |
| Fifty Two Week Change Percent | 422.91666 |
| Fifty Two Week High | 13.2 |
| Fifty Two Week High Change | -0.6499996 |
| Fifty Two Week High Change Percent | -0.049242396 |
| Fifty Two Week Low | 1.47 |
| Fifty Two Week Low Change | 11.08 |
| Fifty Two Week Low Change Percent | 7.5374146 |
| Fifty Two Week Range | 1.47 - 13.2 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,721,395,800,000 |
| Float Shares | 4,233,224 |
| Forward Eps | -2.47667 |
| Forward P E | -5.067288 |
| Free Cashflow | -49,240,248 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 104 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.27708 |
| Held Percent Institutions | 0.68843 |
| Implied Shares Outstanding | 24,716,672 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-07-19 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California. |
| Long Name | Artiva Biotherapeutics, Inc. |
| Market | us_market |
| Market Cap | 310,194,240 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_672643147 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -83,865,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 308,340,483 |
| Number Of Analyst Opinions | 5 |
| Open | 12.68 |
| Operating Cashflow | -76,751,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 858 267 4467 |
| Post Market Change | -0.006000519 |
| Post Market Change Percent | -0.047812898 |
| Post Market Price | 12.544 |
| Post Market Time | 1,776,469,803 |
| Previous Close | 12.11 |
| Price Eps Current Year | -3.7801206 |
| Price Hint | 2 |
| Price To Book | 2.7722554 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.312 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.16667 |
| Region | US |
| Regular Market Change | 0.440001 |
| Regular Market Change Percent | 3.63337 |
| Regular Market Day High | 13.2 |
| Regular Market Day Low | 11.11 |
| Regular Market Day Range | 11.11 - 13.2 |
| Regular Market Open | 12.68 |
| Regular Market Previous Close | 12.11 |
| Regular Market Price | 12.55 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 743,403 |
| Return On Assets | -0.32968 |
| Return On Equity | -0.56549 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 24,716,672 |
| Shares Percent Shares Out | 0.006 |
| Shares Short | 148,199 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 148,835 |
| Short Name | Artiva Biotherapeutics, Inc. |
| Short Percent Of Float | 0.0147 |
| Short Ratio | 0.81 |
| Source Interval | 15 |
| State | CA |
| Symbol | ARTV |
| Target High Price | 23.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 17.0 |
| Target Median Price | 18.0 |
| Total Cash | 108,008,000 |
| Total Cash Per Share | 4.37 |
| Total Debt | 10,942,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.43 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.04415 |
| Two Hundred Day Average Change | 8.50585 |
| Two Hundred Day Average Change Percent | 2.103248 |
| Type Disp | Equity |
| Volume | 743,403 |
| Website | https://www.artivabio.com |
| Zip | 92,121 |